Argus keeps a Buy rating and $550 price target on Humana while naming the stock as one of the firm’s 2024 Top Picks. The demographics of an aging population will be a tailwind for Humana’s growth as this trend expands the addressable market for Medicare Advantage, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUM:
- M & A News: Cigna (NYSE:CI) Explores Medicare Business Sale
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024
- Oppenheimer says Aetna’s PAD prior authorization spills over to Humana
- 5 Top Healthcare Stocks to Buy Now, According to Analysts – December 2023
- UnitedHealth price target raised to $675 from $660 at BofA
